The most common comorbidities in patients with Ehlers-Danlos syndrome: a 15-year nationwide population-based cohort study
Abstract
Abstract Objectives Ehlers-Danlos syndrome (EDS) constitutes a group of connective tissue diseases with variable organ dysfunction. We aimed to examine the comorbidity burden in patients with EDS. Methods A nationwide population-based cohort study linking data from Danish registers from the year 2000–2014. The EDS cohort was identified using the International Classification of Diseases version 10 (ICD-10) EDS code. The control cohort was formed from the Danish general population by randomly matching the EDS cohort in a ratio of 1:25 by sex and date of birth. Hospital contacts were used to identify the most frequently occurring ICD-10 codes. We investigated the frequencies of the disease categories and unique ICD-10 codes and compared these between the cohorts. Results The EDS cohort included 1,319 patients and the control cohort 46,700 patients. All disease categories and ICD-10 codes were significantly more frequent within the EDS cohort, especially those related to common manifestations of EDS. Other comorbidities such as asthma, pneumonia, gastrointestinal functional disorders, and hernias were also significantly more common in the EDS cohort. Conclusions The most common comorbidities in Danish patients with EDS were gastrointestinal functional disorders, hernias, asthma, pneumonia, and osteoporosis. The causality between these comorbidities and EDS should be investigated further. Implications for Rehabilitation Ehlers-Danlos syndrome constitutes a group of connective…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 46,700 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.